|
1 |
Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
Pather, Shanti. - Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg, 2023
|
|
|
|
2 |
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
Pather, Shanti. - Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg, 2023
|
|
|
3 |
Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
Enthalten in Journal of cancer research and clinical oncology 6.1.2023: 1-14
|
|
|
|
4 |
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Salomon, Nadja. - Mainz : Universitätsbibliothek der Johannes Gutenberg-Universität Mainz, 2022
|
|
|
|
5 |
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
Quandt, Jasmin. - Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg, 2022
|
|
|
|
6 |
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Enthalten in Cancer immunology immunotherapy 31.12.2021: 1-14
|
|
|
|
7 |
Racing for a SARS‐CoV‐2 vaccine
Enthalten in European Molecular Biology Organization: EMBO molecular medicine 27.09.2021. 2 S.
|
|
|
|
8 |
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Enthalten in Nature medicine Bd. 31, 6.1.2025, Nr. 1, date:1.2025: 152-164
|
|
|
|
9 |
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Enthalten in Nature medicine Bd. 29, 23.10.2023, Nr. 11, date:11.2023: 2844-2853
|
|
|
|
10 |
Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide
Enthalten in Journal of nanobiotechnology Bd. 16, 13.4.2018, Nr. 1, date:12.2018: 1-21
|
|
Administration
